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Letter to the editor
Rodrigues and colleagues recently presented in this jour-
nal a comprehensive and timely review of the current
state of knowledge about immunity to visceralizing spe-
cies of Leishmania in humans and in animal models [1].
We read with particular interest the topic they devoted
to studies that evaluated the role of antibodies, B cells
and T follicular helper cells during infections with these
intracellular parasites. We strongly agree with the au-
thors’ conclusions about the need to reassess the role of
antibodies in these infections, wherein they state that
“Rather than considering the role of antibodies solely as
pathological or irrelevant, it is perhaps wiser to acknow-
ledge that these molecules may play both protective and
non-protective roles during VL”. However, we would like
to add further information from studies that provide im-
portant evidence and concepts that also support a crucial
role of antibodies during infections with Leishmania and
that were not considered in their review.
As pointed out by Arturo Casadevall, the rationale for
dichotomizing types of immunity against extracellular
and intracellular pathogens into antibody-mediated and
cell-mediated, respectively, is based on concepts that
probably originated in the great debate between scientists
advocating humoral or cellular immunity at the beginning
of the 20th century [2]. However, this concept cannot be
applied to every known pathogen, whereby antibodies
have been shown to protect against at least some intra-
cellular pathogens such as Trypanosoma cruzi [3, 4],
Histoplasma capsulatum [5] and Mycobacterium tuber-
culosis [6]. Since the majority of early studies on the
leishmaniases did not correlate antibody-mediated im-
munity with protection, many questions about the role
of B lymphocytes and antibodies during such infections
remained unanswered. However, an initial proof of con-
cept that antibodies can be important for controlling
infections with Leishmania comes from the observation
that pathogenic Trypanosomatidae express receptors
for IgG Fc [7, 8] or proteases for IgG [9], possibly to es-
cape from this effector mechanism.
In the early 80’s Anderson and colleagues [10] demon-
strated that the protective effect of a monoclonal anti-
body raised against L. mexicana was dependent on the
number of antibody-opsonized parasites inoculated into
BALB/c mice [10]. Furthermore, another study showed
that monoclonal antibodies raised against L. infantum
conferred passive cross-protection against infections with
L. amazonensis and L. major in mice [11]. As addressed by
Rodrigues and colleagues [1], a study demonstrated that
protective immunity against L. major required efficient up-
take of IgG-opsonized parasites by dendritic cells through
Fc-gamma receptors (FcγR) I and III [12]. More recent
work revealed that elimination of L. amazonensis depends
in part on the FcγR common-chain and NADPH oxidase-
generated superoxide from infected macrophages in vitro
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[13]. In contrast, a study showed that interactions of
mouse IgG1 with FcγRIII is detrimental in infections
with L. mexicana, but not interactions with IgG2a/c or
IgG3 [14]. Together, these data suggest that the signal-
ing pathways through which phagocytes are activated
might be fundamental for the functional profile that
these cells will acquire and, therefore, for their effects
on polarizing the cell populations that will comprise
Leishmania-specific acquired immunity.
Notably, mice that lack immunoglobulin-bearing B
cells (JhD BALB/c) are considered to be relatively resist-
ant to infection with L. pifanoi, L. amazonensis and L.
infantum and passive transfer of B cells, immune serum
or purified antibodies to chronically infected JhD BALB/c
mice restored susceptibility to infection, respectively
[15–17]. In addition, μMT mice (assumed to lack mature B
cells) also exhibit a relative resistance when infected with
L. major LV39 (BALB/c) [18] or L. donovani (C57BL/6)
[19]; however, other work indicates that μ-chain-deficient
mice possess functional B-1 cells and can produce non-
specific IgG [20, 21]. Indeed, the studies mentioned above
did not discriminate between subsets of cells derived from
B lymphocytes such as plasma cells, regulatory B cells or
marginal zone B cells, which exhibit different functions
depending on the context of infection with Leishmania
[22–28]. We also highlight that, while mice (BALB/c or
C57BL/6) are acutely susceptible to these parasites,
they do not develop chronic and progressive disease
after infection with L. donovani or L. infantum [29].
Therefore, the role of antibodies in these mouse models
of visceral leishmaniasis (VL) and its translation into
immunopathological features observed in progressive
disease as seen in humans and non-human primates,
dogs and hamsters, may warrant reinterpretation. Ac-
cordingly, Reis and colleagues [30] observed a strong
correlation between levels of IgG1 antibodies specific
for soluble antigens from L. infantum promastigotes
and an asymptomatic outcome of infection and also a
correlation between IgG2 of the same specificity and
manifestation of disease in dogs. In another study, Oli-
veira and colleagues [31] observed that dogs presenting
with asymptomatic infections with L. infantum have
significantly lower levels of IgG2 antibodies specific for
a crude antigen extract from these parasites than symp-
tomatic dogs. Interestingly, these authors also observed
that dogs vaccinated with Leishimmune® (Fort Dodge
Animal Health) and supposedly protected against dis-
ease, present negligible levels of IgG1, IgG3 e IgG4
antibodies and high levels of IgG2 antibodies against
this crude antigen extract.
As pointed out by Rodrigues and colleagues in their
review [1], the dose of parasites may influence the result-
ing immune response [32]. Menon & Bretscher [33] also
determined that the dose of Leishmania affects the
outcome of infection even in genetically susceptible
hosts: BALB/c mice can control infection with L. major,
a visceralizing parasite in this host, if they receive a low
dose of parasites. Dominguez and colleagues [34] and
Moreno and colleagues [35] showed that natural anti-
bodies present in normal human sera rapidly (i.e. in
2.5 min) cause lysis of 85–95 % of infective metacyclic
Leishmania promastigotes by means of the classical
pathway of complement. Thus, Leishmania-reactive anti-
bodies presenting an adequate profile may result in man-
ageable doses of parasites at crucial initial stages of
infection with Leishmania by promoting lysis of infective
promastigotes inoculated by vectors. This mechanism
does not exclude a further role for antibodies with ad-
equate profiles in activating microbicidal mechanisms
and expansion of efficacious effector responses through
appropriate signaling pathways in Leishmania-infected
phagocytic and antigen-presenting cells.
Finally, we wish to point out that not only variability
at the level of protein within IgG subclasses and the dif-
ferent FcR affects effector mechanisms of antibody-
mediated immunity: interactions of IgGs with type I FcR
(the canonical FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa,
FcγRIIIb) or type II FcR (DC-SIGN and CD23) [36]; or
with mannan-binding lectin [37] and the complement
component C1q [38] are also regulated by the patterns of
N-linked, biantennary glycan structures attached to Asn
297 of the IgG heavy chain [39]. In a recent study, we
and our colleagues applied a robust method of IgG Fc
N-glycopeptide profiling that demonstrated profound
alterations in the patterns of IgG Fc N-glycosylation of
VL patients compared with those of asymptomatic indi-
viduals and non-infected controls [40]. In fact, the pro-
file of IgG Fc glycans presented by the VL patients that
we examined is compatible with and may contribute to
the imbalance of the inflammatory milieu that Rodrigues
and colleagues suggest is unfavorable for proper differenti-
ation of T follicular helper cells [1]. In our opinion, those
alterations are extremely relevant and should be consid-
ered in future studies addressing immunopathological or
protective responses in infections with Leishmania, which
might depend on the clinical context after infection and
possibly affect bystander inflammatory processes [41], B
cell activation and regulation [42] and antibody-mediated
effector functions.
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